By Sneha S K and Amina Niasse Feb 23 (Reuters) - Online telehealth company Hims & Hers Health, which sells weight-loss drugs, ...

The telehealth platform expects its growth to continue this year, though its first-quarter guidance came in short of Wall ...

Hims & Hers Health (NYSE:HIMS) executives used the company’s fourth-quarter and full-year 2025 earnings call to emphasize expanding scale, broader specialty breadth, and accelerating international ...

The wellness platform’s results arrived amid heightened legal and regulatory scrutiny over its weight-loss-drug business.

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Oversold Pharma Stocks to Buy Now. Hims & Hers Health, Inc. (NYSE:HIMS) ...

A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age 35. So, while Hims provides access to a number of different prescription ...

In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the ...

Hims & Hers Health Inc HIMS reported financial results for the fourth quarter after the market close on Monday. Here’s a look at the key details from the print. Hims & Hers Health stock is showing ...

Hims & Hers is one of the leading telehealth firms in the US. Since its 2017 launch, the platform has connected patients with healthcare providers across specialties including erectile dysfunction, ...

Hims & Hers Health, Inc. HIMS is in the spotlight Monday as the company prepares to report fourth-quarter earnings after the market closes. Hims stock is trading near recent lows. What’s ahead for ...

The telehealth company posted Q4 earnings per share of $0.08, topping analyst estimates of $0.05. Revenue rose to $617.8 million, compared with consensus expectations of $618.7 million. The results ...

Workers at an Australian start-up have become overnight millionaires as more than after a US telehealth giant swooped in with ...